17 Mar 2023 Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate
15 Mar 2023 GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
08 Mar 2023 OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
22 Feb 2023 LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate
21 Feb 2023 Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
21 Feb 2023 U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
20 Feb 2023 Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
20 Feb 2023 FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review
17 Feb 2023 Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
17 Feb 2023 Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
16 Feb 2023 Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
14 Feb 2023 Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission
10 Feb 2023 Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)
07 Feb 2023 Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson's Disease
03 Feb 2023 INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
30 Jan 2023 CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
26 Jan 2023 AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
25 Jan 2023 Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
25 Jan 2023 Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
20 Jan 2023 LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer
18 Jan 2023 Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
18 Jan 2023 Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
16 Jan 2023 Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®
13 Jan 2023 Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
10 Jan 2023 Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up